{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:55:34Z","timestamp":1787064934004,"version":"build-2736575974"},"reference-count":70,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100001410","name":"CSIR-HRDG","doi-asserted-by":"publisher","award":["CSIR HRDG 09\/1132(0008)\/2019-EMR-I"],"award-info":[{"award-number":["CSIR HRDG 09\/1132(0008)\/2019-EMR-I"]}],"id":[{"id":"10.13039\/501100001410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CHAMC"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Chemotherapy-induced cardiotoxicity is an increasing concern and it is critical to avoid\nheart dysfunction induced by medications used in various cancers. Dysregulated cardiomyocyte\nhomeostasis is a critical phenomenon of drug-induced cardiotoxicity, which hinders the cardiac\ntissue's natural physiological function. Drug-induced cardiotoxicity is responsible for various heart\ndisorders such as myocardial infarction, myocardial hypertrophy, and arrhythmia, among others.\nChronic cardiac stress due to drug toxicity restricts the usage of cancer medications. Anticancer\nmedications can cause a variety of adverse effects, especially cardiovascular toxicity. This review\nis focused on anticancerous drugs anthracyclines, trastuzumab, nonsteroidal anti-inflammatory\nmedications (NSAIDs), and immune checkpoint inhibitors (ICI) and associated pathways attributed\nto the drug-induced cardiotoxicity. Several factors responsible for enhanced cardiotoxicity are\nage, gender specificity, diseased conditions, and therapy are also discussed. The review also highlighted\nthe patents assigned for different methodologies involved in the assessment and reducing\ncardiotoxicity. Recent advancements where the usage of trastuzumab and bevacizumab have\ncaused cardiac dysfunction and their effects alone or in combination on cardiac cells are explained.\nExtensive research on patents associated with protection against cardiotoxicity has shown that\nchemicals like bis(dioxopiperazine)s and manganese compounds were cardioprotective when\ncombined with other selected anticancerous drugs. Numerous patents are associated with druginduced\ntoxicity, prevention, and diagnosis, that may aid in understanding the current issues and\ndeveloping novel therapies with safer cardiovascular outcomes. Also, the advancements in technology\nand research going on are yet to be explored to overcome the present issue of cardiotoxicity\nwith the development of new drug formulations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1871525721666230120155734","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T01:45:58Z","timestamp":1674438358000},"page":"28-39","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Patent Review on Cardiotoxicity of Anticancerous Drugs"],"prefix":"10.2174","volume":"22","author":[{"given":"Renu","family":"Bhadana","sequence":"first","affiliation":[{"name":"Center for Emerging Diseases, Department of Biotechnology, Jaypee Institute of Information Technology, A-10, Sector-\n62, Noida 201307, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibha","family":"Rani","sequence":"additional","affiliation":[{"name":"Center for Emerging Diseases, Department of Biotechnology, Jaypee Institute of Information Technology, A-10, Sector-\n62, Noida 201307, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1152\/physrev.00036.2019","volume":"101","author":"Quinn T.A.","year":"2021","unstructured":"Quinn T.A.; Kohl P.; Cardiac mechano-electric coupling: Acute effects of mechanical stimulation on heart rate and rhythm. Physiol Rev 2021,101(1),37-92","journal-title":"Physiol Rev"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","volume":"64","author":"Vejpongsa P.","year":"2014","unstructured":"Vejpongsa P.; Yeh E.T.H.; Prevention of anthracycline-induced cardiotoxicity: Challenges and opportunities.. J Am Coll Cardiol 2014,64(9),938-945","journal-title":"J Am Coll Cardiol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/med.21463","volume":"38","author":"Zheng P.P.","year":"2018","unstructured":"Zheng P.P.; Li J.; Kros J.M.; Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. Med Res Rev 2018,38(1),325-376","journal-title":"Med Res Rev"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00228-016-2043-z","volume":"72","author":"Niedrig D.","year":"2016","unstructured":"Niedrig D.; Maechler S.; Hoppe L.; Corti N.; Kovari H.; Russmann S.; Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: Administration of interacting co-medication and QT prolongation. Eur J Clin Pharmacol 2016,72(7),859-867","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=5","volume":"80","author":"Ai D.","year":"2014","unstructured":"Ai D.; Banchs J.; Owusu-Agyemang P.; Cata J.P.; Chemotherapy-induced cardiovascular toxicity: Beyond anthracyclines. Minerva Anestesiol 2014,80(5)","journal-title":"Minerva Anestesiol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1042\/CS20190653","volume":"134","author":"Dadson K.","year":"2020","unstructured":"Dadson K.; Calvillo-Arg\u00fcelles O.; Thavendiranathan P.; Billia F.; Anthracycline-induced cardiomyopathy: Cellular and molecular mechanisms. Clin Sci (Lond) 2020,134(13),1859-1885","journal-title":"Clin Sci (Lond)"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1042\/CS20070430","volume":"115","author":"Muslin A.J.","year":"2008","unstructured":"Muslin A.J.; MAPK signalling in cardiovascular health and disease: Molecular mechanisms and therapeutic targets. Clin Sci (Lond) 2008,115(7),203-218","journal-title":"Clin Sci (Lond)"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"847012","DOI":"10.3389\/fcvm.2022.847012","volume":"9","author":"Morelli M.B.","year":"2022","unstructured":"Morelli M.B.; Bongiovanni C.; Da Pra S.; Miano C.; Sacchi F.; Lauriola M.; D\u2019Uva G.; Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection. Front Cardiovasc Med 2022,9,847012","journal-title":"Front Cardiovasc Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/cmdc.202000131","volume":"15","author":"Martins-Teixeira M.B.","year":"2020","unstructured":"Martins-Teixeira M.B.; Carvalho I.; Antitumour Anthracyclines: Progress and Perspectives. ChemMedChem 2020,15(11),933-948","journal-title":"ChemMedChem"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"Cardinale D.","year":"2015","unstructured":"Cardinale D.; Colombo A.; Bacchiani G.; Tedeschi I.; Meroni C.A.; Veglia F.; Civelli M.; Lamantia G.; Colombo N.; Curigliano G.; Fiorentini C.; Cipolla C.M.; Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015,131(22),1981-1988","journal-title":"Circulation"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1042\/CS20200301","volume":"135","author":"Narezkina A.","year":"2021","unstructured":"Narezkina A.; Narayan H.K.; Zemljic-Harpf A.E.; Molecular mechanisms of anthracycline cardiovascular toxicity. Clin Sci (Lond) 2021,135(10),1311-1332","journal-title":"Clin Sci (Lond)"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fphys.2018.00167","volume":"9","author":"Varricchi G.","year":"2018","unstructured":"Varricchi G.; Ameri P.; Cadeddu C.; Ghigo A.; Madonna R.; Marone G.; Mercurio V.; Monte I.; Novo G.; Parrella P.; Pirozzi F.; Pecoraro A.; Spallarossa P.; Zito C.; Mercuro G.; Pagliaro P.; Tocchetti C.G.; Antineoplastic drug-induced cardiotoxicity: A redox perspective. Front Physiol 2018,9,167","journal-title":"Front Physiol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S1470-2045(14)70080-4","volume":"15","author":"Gianni L.","year":"2014","unstructured":"Gianni L.; Eiermann W.; Semiglazov V.; Lluch A.; Tjulandin S.; Zambetti M.; Moliterni A.; Vazquez F.; Byakhov M.J.; Lichinitser M.; Climent M.A.; Ciruelos E.; Ojeda B.; Mansutti M.; Bozhok A.; Magazz\u00f9 D.; Heinzmann D.; Steinseifer J.; Valagussa P.; Baselga J.; Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 2014,15(6),640-647","journal-title":"Lancet Oncol"},{"key":"ref=14","first-page":"253","volume":"44","author":"Sarosiek T.","year":"2018","unstructured":"Sarosiek T.; Morawski P.; Trastuzumab and its biosimilars. Pol Merkuriusz Lek 2018,44(263),253-257","journal-title":"Pol Merkuriusz Lek"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.3390\/cancers14205115","volume":"14","author":"Vivekanandhan S.","year":"2022","unstructured":"Vivekanandhan S.; Knutson K.L.; Resistance to Trastuzumab. Cancers (Basel) 2022,14(20),5115","journal-title":"Cancers (Basel)"},{"key":"ref=16","first-page":"1","author":"Dokmanovic M.","year":"2014","unstructured":"Dokmanovic M.; Wu W.J.; Trastuzumab-induced HER2 phosphorylation: Exploring the mechanisms and implications. Receptors Clin Investig 2014,1","journal-title":"Receptors Clin Investig"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"10261","DOI":"10.1074\/jbc.273.17.10261","volume":"273","author":"Zhao Y.","year":"1998","unstructured":"Zhao Y.; Sawyer D.R.; Baliga R.R.; Opel D.J.; Han X.; Marchionni M.A.; Kelly R.A.; Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998,273(17),10261-10269","journal-title":"J Biol Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","volume":"128","author":"Junttila T.T.","year":"2011","unstructured":"Junttila T.T.; Li G.; Parsons K.; Phillips G.L.; Sliwkowski M.X.; Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011,128(2),347-356","journal-title":"Breast Cancer Res Treat"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ccr.2009.03.020","volume":"15","author":"Junttila T.T.","year":"2009","unstructured":"Junttila T.T.; Akita R.W.; Parsons K.; Fields C.; Lewis Phillips G.D.; Friedman L.S.; Sampath D.; Sliwkowski M.X.; Ligand-independent HER2\/HER3\/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009,15(5),429-440","journal-title":"Cancer Cell"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nm.2309","volume":"17","author":"Zhang S.","year":"2011","unstructured":"Zhang S.; Huang W.C.; Li P.; Guo H.; Poh S.B.; Brady S.W.; Xiong Y.; Tseng L.M.; Li S.H.; Ding Z.; Sahin A.A.; Esteva F.J.; Hortobagyi G.N.; Yu D.; Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 2011,17(4),461-469","journal-title":"Nat Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/2042098614529603","volume":"5","author":"Onitilo A.A.","year":"2014","unstructured":"Onitilo A.A.; Engel J.M.; Stankowski R.V.; Cardiovascular toxicity associated with adjuvant trastuzumab therapy: Prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf 2014,5(4),154-166","journal-title":"Ther Adv Drug Saf"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"e0276541","DOI":"10.1371\/journal.pone.0276541","volume":"17","author":"Hasbullah J.S.","year":"2022","unstructured":"Hasbullah J.S.; Scott E.N.; Bhavsar A.P.; Gunaretnam E.P.; Miao F.; Soliman H.; Carleton B.C.; Ross C.J.D.; All-trans retinoic acid (ATRA) regulates key genes in the RARG-TOP2B pathway and reduces anthracycline-induced cardiotoxicity. PLoS One 2022,17(11),e0276541","journal-title":"PLoS One"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","volume":"64","author":"Vejpongsa P.","year":"2014","unstructured":"Vejpongsa P.; Yeh E.T.H.; Prevention of anthracycline-induced cardiotoxicity: Challenges and opportunities.. J Am Coll Cardiol 2014,64(9),938-945","journal-title":"J Am Coll Cardiol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"6095","DOI":"10.18632\/oncotarget.23543","volume":"9","author":"Jiang J.","year":"2018","unstructured":"Jiang J.; Mohan N.; Endo Y.; Shen Y.; Wu W.J.; Type IIB DNA topoisomerase is downregulated by trastuzumab and doxorubicin to synergize cardiotoxicity. Oncotarget 2018,9(5),6095-6108","journal-title":"Oncotarget"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1634\/theoncologist.2016-0406","volume":"22","author":"Yu A.F.","year":"2017","unstructured":"Yu A.F.; Singh J.C.; Wang R.; Liu J.E.; Eaton A.; Oeffinger K.C.; Steingart R.M.; Hudis C.A.; Dang C.T.; Cardiac safety of dual anti\u2010HER2 therapy in the neoadjuvant setting for treatment of HER2\u2010positive breast cancer. Oncologist 2017,22(6),642-647","journal-title":"Oncologist"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/ijc.29378","volume":"137","author":"Poovassery J.S.","year":"2015","unstructured":"Poovassery J.S.; Kang J.C.; Kim D.; Ober R.J.; Ward E.S.; Antibody targeting of HER2\/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer. Int J Cancer 2015,137(2),267-277","journal-title":"Int J Cancer"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/ehf2.13756","volume":"9","author":"Berecz T.","year":"2022","unstructured":"Berecz T.; Yiu A.; Vittay O.; Orsolits B.; Mioulane M.; Remedios C.G.; Ketteler R.; Merkely B.; Ap\u00e1ti \u00c1.; Harding S.E.; Hellen N.; Foldes G.; Transcriptional co\u2010activators YAP1\u2013TAZ of Hippo signalling in doxorubicin\u2010induced cardiomyopathy. ESC Heart Fail 2022,9(1),224-235","journal-title":"ESC Heart Fail"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"9330","DOI":"10.1158\/0008-5472.CAN-08-4597","volume":"69","author":"Scheuer W.","year":"2009","unstructured":"Scheuer W.; Friess T.; Burtscher H.; Bossenmaier B.; Endl J.; Hasmann M.; Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009,69(24),9330-9336","journal-title":"Cancer Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"114147","DOI":"10.1016\/j.bcp.2020.114147","volume":"180","author":"Bindu S.","year":"2020","unstructured":"Bindu S.; Mazumder S.; Bandyopadhyay U.; Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol 2020,180,114147","journal-title":"Biochem Pharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"Bombardier C.","year":"2000","unstructured":"Bombardier C.; Laine L.; Reicin A.; Shapiro D.; Burgos-Vargas R.; Davis B.; Day R.; Ferraz M.B.; Hawkey C.J.; Hochberg M.C.; Kvien T.K.; Schnitzer T.J.; Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2, 1528.2000,343(21),1520-1528","journal-title":"N Engl J Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1056\/NEJMoa050330","volume":"352","author":"Nussmeier N.A.","year":"2005","unstructured":"Nussmeier N.A.; Whelton A.A.; Brown M.T.; Langford R.M.; Hoeft A.; Parlow J.L.; Boyce S.W.; Verburg K.M.; Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005,352(11),1081-1091","journal-title":"N Engl J Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","volume":"19","author":"Lyon A.R.","year":"2018","unstructured":"Lyon A.R.; Yousaf N.; Battisti N.M.L.; Moslehi J.; Larkin J.; Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 2018,19(9),e447-e458","journal-title":"Lancet Oncol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.cjca.2018.03.012","volume":"34","author":"Mir H.","year":"2018","unstructured":"Mir H.; Alhussein M.; Alrashidi S.; Alzayer H.; Alshatti A.; Valettas N.; Mukherjee S.D.; Nair V.; Leong D.P.; Cardiac complications associated with checkpoint inhibition: A systematic review of the literature in an important emerging area. Can J Cardiol 2018,34(8),1059-1068","journal-title":"Can J Cardiol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.1158\/1078-0432.CCR-18-4083","volume":"25","author":"Ji C.","year":"2019","unstructured":"Ji C.; Roy M.D.; Golas J.; Vitsky A.; Ram S.; Kumpf S.W.; Martin M.; Barletta F.; Meier W.A.; Hooper A.T.; Sapra P.; Khan N.K.; Finkelstein M.; Guffroy M.; Buetow B.S.; Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors. Clin Cancer Res 2019,25(15),4735-4748","journal-title":"Clin Cancer Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"Johnson D.B.","year":"2016","unstructured":"Johnson D.B.; Balko J.M.; Compton M.L.; Chalkias S.; Gorham J.; Xu Y.; Hicks M.; Puzanov I.; Alexander M.R.; Bloomer T.L.; Becker J.R.; Slosky D.A.; Phillips E.J.; Pilkinton M.A.; Craig-Owens L.; Kola N.; Plautz G.; Reshef D.S.; Deutsch J.S.; Deering R.P.; Olenchock B.A.; Lichtman A.H.; Roden D.M.; Seidman C.E.; Koralnik I.J.; Seidman J.G.; Hoffman R.D.; Taube J.M.; Diaz L.A.; Anders R.A.; Sosman J.A.; Moslehi J.J.; Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016,375(18),1749-1755","journal-title":"N Engl J Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJM199506293322602","volume":"332","author":"Lipshultz S.E.","year":"1995","unstructured":"Lipshultz S.E.; Lipsitz S.R.; Mone S.M.; Goorin A.M.; Sallan S.E.; Sanders S.P.; Orav E.J.; Gelber R.D.; Colan S.D.; Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995,332(26),1738-1744","journal-title":"N Engl J Med"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1200\/JCO.1995.13.7.1546","volume":"13","author":"Sorensen K.","year":"1995","unstructured":"Sorensen K.; Levitt G.; Sebag-Montefiore D.; Bull C.; Sullivan I.; Cardiac function in Wilms\u2019 tumor survivors. J Clin Oncol 1995,13(7),1546-1556","journal-title":"J Clin Oncol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","volume":"26","author":"Hershman D.L.","year":"2008","unstructured":"Hershman D.L.; McBride R.B.; Eisenberger A.; Tsai W.Y.; Grann V.R.; Jacobson J.S.; Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 2008,26(19),3159-3165","journal-title":"J Clin Oncol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1067\/mnc.2000.103324","volume":"7","author":"Jain D.","year":"2000","unstructured":"Jain D.; Cardiotoxicity of doxorubicin and other anthracycline derivatives. J Nucl Cardiol 2000,7(1),53-62","journal-title":"J Nucl Cardiol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0022-3476(80)80128-4","volume":"97","author":"Biancaniello T.","year":"1980","unstructured":"Biancaniello T.; Meyer R.A.; Wong K.Y.; Sager C.; Kaplan S.; Doxorubicin cardiotoxicity in children. J Pediatr 1980,97(1),45-50","journal-title":"J Pediatr"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1161\/CIRCRESAHA.121.319901","volume":"130","author":"Wilcox N.S.","year":"2022","unstructured":"Wilcox N.S.; Rotz S.J.; Mullen M.; Song E.J.; Ky Hamilton B.; Moslehi J.; Armenian S.H.; Wu J.C.; Rhee J.W.; Ky B.; Sex-specific cardiovascular risks of cancer and its therapies. Circ Res 2022,130(4),632-651","journal-title":"Circ Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.3390\/jcm11175167","volume":"11","author":"Simek S.","year":"2022","unstructured":"Simek S.; Lue B.; Rao A.; Ravipati G.; Vallabhaneni S.; Zhang K.; Zaha V.G.; Chandra A.; Gender differences in diagnosis, prevention, and treatment of cardiotoxicity in cardio-oncology. J Clin Med 2022,11(17),5167","journal-title":"J Clin Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","volume":"342","author":"Felker G.M.","year":"2000","unstructured":"Felker G.M.; Thompson R.E.; Hare J.M.; Hruban R.H.; Clemetson D.E.; Howard D.L.; Baughman K.L.; Kasper E.K.; Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000,342(15),1077-1084","journal-title":"N Engl J Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1161\/01.CIR.100.9.999","volume":"100","author":"Mann D.L.","year":"1999","unstructured":"Mann D.L.; Mechanisms and models in heart failure: A combinatorial approach. Circulation 1999,100(9),999-1008","journal-title":"Circulation"},{"key":"ref=45","first-page":"176","volume":"27","author":"Dr\u00edmal J.","year":"2006","unstructured":"Dr\u00edmal J.; Z\u00farov\u00e1-Nedelcevov\u00e1 J.; Knezl V.; Sotn\u00edkov\u00e1 R.; Navarov\u00e1 J.; Cardiovascular toxicity of the first line cancer chemotherapeutic agents: Doxorubicin, cyclophosphamide, streptozotocin and bevacizumab. Neuroendocrinol Lett 2006,27(Suppl. 2),176-179","journal-title":"Neuroendocrinol Lett"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1038\/sj.onc.1202526","volume":"18","author":"Pegram M.","year":"1999","unstructured":"Pegram M.; Hsu S.; Lewis G.; Pietras R.; Beryt M.; Sliwkowski M.; Coombs D.; Baly D.; Kabbinavar F.; Slamon D.; Inhibitory effects of combinations of HER-2\/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999,18(13),2241-2251","journal-title":"Oncogene"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"Piccart-Gebhart M.J.","year":"2005","unstructured":"Piccart-Gebhart M.J.; Procter M.; Leyland-Jones B.; Goldhirsch A.; Untch M.; Smith I.; Gianni L.; Baselga J.; Bell R.; Jackisch C.; Cameron D.; Dowsett M.; Barrios C.H.; Steger G.; Huang C.S.; Andersson M.; Inbar M.; Lichinitser M.; L\u00e1ng I.; Nitz U.; Iwata H.; Thomssen C.; Lohrisch C.; Suter T.M.; R\u00fcschoff J.; S\u00fct\u0151 T.; Greatorex V.; Ward C.; Straehle C.; McFadden E.; Dolci M.S.; Gelber R.D.; Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005,353(16),1659-1672","journal-title":"N Engl J Med"},{"key":"ref=48","author":"Sidorenko J.S.","year":"2004","unstructured":"Sidorenko J.S.; Sycheva E.A.; Maksimova N.A.; Method for producing ultrasonic antracycline- induced cardiotoxicity evaluation in oncological patients. 2004"},{"key":"ref=49","author":"Bitter H.M.L.","year":"2011","unstructured":"Bitter H.M.L.; Kolaja K.L.; Dhaw P.; Uppal H.; Gonzaludo N.; Prediction of cardiotoxicity. 2011"},{"key":"ref=50","author":"Bacus S.S.","year":"2013","unstructured":"Bacus S.S.; Methods for predicting cardiac toxicity. 2013"},{"key":"ref=51","author":"Deichmann O.D.","year":"2014","unstructured":"Deichmann O.D.; Fang Y.; Ferrie A.M.; Hu H.; Wu Q.; Label free method for assessing chemical cardiotoxicity. 2014"},{"key":"ref=52","author":"Carleton B.","year":"2016","unstructured":"Carleton B.; Hayden M.R.; Ross C.J.; Aminkeng F.; Retinoic acid receptor gamma (RARG) gene polymorphisms predictive of Anthracycline-induced cardiotoxicity (ACT). 2016"},{"key":"ref=53","author":"Roche B.M.","year":"2016","unstructured":"Roche B.M.; Henderson K.A.; Use of 31p NMR spectroscopy of whole heart energetics for detection of drug-induced cardiotoxicity. 2016"},{"key":"ref=54","author":"Yasuda K.","year":"2016","unstructured":"Yasuda K.; Kaneko T.; Nomura F.; Method and apparatus for testing cardiotoxicity and evaluating cardiomyocytes. 2016"},{"key":"ref=55","author":"Teplyakov A.T.","year":"2019","unstructured":"Teplyakov A.T.; Grakova E.V.; Shilov S.N.; Berezikova E.N.; Popova A.A.; Neupokoeva M.N.; Method for predicting development of cardiotoxicity in patients with breast cancer within 12 months after chemotherapy with antracyclic drugs. 2019"},{"key":"ref=56","author":"Teplyakov A.T.","year":"2020","unstructured":"Teplyakov A.T.; Grakova E.V.; Shilov S.N.; Berezikova E.N.; Popova A.A.; Neupokoeva M.N.; Kopeva K.V.; Method for prediction of anthracycline-induced cardiotoxicity in women with breast cancer. 2020"},{"key":"ref=57","author":"Coulombe K.L.K.","year":"2020","unstructured":"Coulombe K.L.K.; Rupert C.E.; Kofron C.M.; Choi B.R.; Kim T.; Mende U.; A human in vitro cardiotoxicity model. 2020"},{"key":"ref=58","author":"Speyer J.L.","year":"1998","unstructured":"Speyer J.L.; Muggia F.M.; Green M.D.; Reduction of anthracycline-induced cardiotoxicity. 1998"},{"key":"ref=59","author":"Towart R.","year":"2000","unstructured":"Towart R.; Karlsson J.O.G.; Jynge P.; Reduction of cardiotoxicity of an antitumor agent using manganese compound. 2000"},{"key":"ref=60","author":"Sreedhara A.","year":"2012","unstructured":"Sreedhara A.; Lukas C.A.; Christina H.D.T.P.; Mark C.B.; Emma L.C.; Zephania W.K.G.; Lada M.; Jayantha R.; Graham A.R.; Ru A.W.; Use of HER2-dimerization inhibitor pertuzumab and products containing pertuzumab. 2012"},{"key":"ref=61","author":"Jay S.M.","year":"2017","unstructured":"Jay S.M.; Griffith L.G.; Lee R.T.; Neuregulin dimer for an ErbB\/HER receptor for use in reducing cardiotoxicity. 2017"},{"key":"ref=62","author":"Armstrong C.G.","year":"2017","unstructured":"Armstrong C.G.; Kim K.J.; Pham L.M.L.; Park E.; Zhong Z.; Huang G.; Pharmaceutical composition and methods for countering chemotherapy-induced cardiotoxicity. 2017"},{"key":"ref=63","author":"Armstrong C.G.","year":"2021","unstructured":"Armstrong C.G.; Kim K.J.; Pham L.M.L.; Park E.; Zhong Z.; Huang G.; W J.C.; Elmer S.P.; Visuthikraisee V.; Cadag E.M.G.; Freeman T.B.; Lum P.Y.; Pharmaceutical\u2019s compositions and methods for controlling cardiotoxicity caused by chemotherapy. 2021"},{"key":"ref=64","author":"Asp B.","year":"2004","unstructured":"Asp B.; Ogden A.; Miller L.; Podesta A.; Method for the treatment of cardiotoxicity induced by antitumor compounds. 2004"},{"key":"ref=65","author":"Wang C.","year":"2020","unstructured":"Wang C.; Lue Y.; Swerdloff R.; Methods for reducing cardiotoxicity from chemotherapy by administering humanin analogue compositions. 2020"},{"key":"ref=66","author":"Freudenberger R.","year":"2008","unstructured":"Freudenberger R.; Use of oxypurinol as an inhibitor of antineoplastic agent-induced cardiotoxicity. 2008"},{"key":"ref=67","author":"Krapcho A.P.","year":"1996","unstructured":"Krapcho A.P.; Hacker M.P.; Cavalletti E.; 6,9-Bisl(2-aminoethyl) aminobenzo gisoquinoline-5,10. dione dimaleate; an azaanthracenedione with reduced cardiotoxicity. 1996"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/j.celrep.2018.08.079","volume":"24","author":"Blinova K.","year":"2018","unstructured":"Blinova K.; Dang Q.; Millard D.; Smith G.; Pierson J.; Guo L.; Brock M.; Lu H. R.; Kraushaar U.; Zeng H.; Shi H.; Zhang X.; Sawada K.; Osada T.; Kanda Y.; Sekino Y.; Pang L.; Feaster T.K.; Kettenhofen R.; Stockbridge N.; Strauss D.G.; Gintant G.; International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment. Cell reports 2018,24(13),3582-3592","journal-title":"Cell reports"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"12060","DOI":"10.1038\/s41598-020-68907-1","volume":"10","author":"Golforoush P.A.","year":"2020","unstructured":"Golforoush P.A.; Narasimhan P.; Chaves-Guerrero P.P.; Lawrence E.; Newton G.; Yan R.; Harding S.E.; Perrior T.; Chapman K.L.; Schneider M.D.; Selective protection of human cardiomyocytes from anthracycline cardiotoxicity by small molecule inhibitors of MAP4K4. Sci Rep 2020,10(1),12060","journal-title":"Sci Rep"},{"key":"ref=70","author":"Tsai J.","year":"2016","unstructured":"Tsai J.; Lam J.; Pike N.K.; Armstrong C.G.; Modulation of druginduced cardiotoxicity. 2016"}],"container-title":["Cardiovascular &amp; Hematological Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871525721666230120155734","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/212981\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871525721666230120155734","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T08:43:49Z","timestamp":1698396229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/212981\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871525721666230120155734","relation":{},"ISSN":["1871-5257"],"issn-type":[{"value":"1871-5257","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}